Skip to content

Gyre Therapeutics

US · GYRE #3470 by market cap Listed 2006
4.21 -0.31 -6.86%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 4.51 -0.22%
After-hours 4.21 0.00%
7.554.014.212026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on GYRE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -41.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 2.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth B+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 4.5% Better than 45%
Net income CAGR (3Y) 29.7% Better than 80%
Profitability B-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 95.4% Better than 98%
Operating margin 9.9% Better than 51%
Net margin 4.3% Better than 41%
Return on equity 5.9% Better than 39%
Return on invested capital 4.5% Better than 42%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -39.1% Better than 11%
6-month return -30.5% Better than 18%
12-month return (ex latest month) -22.4% Better than 13%
Distance below 52-week high 53.9% Better than 15%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.6x Better than 88%
Debt to assets 0.6% Better than 95%
Interest coverage 638.8x Better than 98%
Free cash flow / net income 33.7% Better than 9%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.32%
1M -31.77%
3M -40.03%
6M -30.30%
YTD -40.37%
1Y -43.79%
3Y -71.32%
5Y +31.65%

Key statistics

Price & volume

Prev close
4.52
Open
4.40
Day range
4.13 - 4.51
Avg price
4.28
Volume
240.14K
Turnover
1.03M
Amplitude
8.41%
52-week range
3.97 - 9.14

Valuation

P/E
210.50
P/E (TTM)
-16.19
P/B
4.27
EPS
0.02
Net profit
2.19M
Net assets
107.92M

Share structure

Market cap
460.79M
Float cap
165.70M
Shares out
109.45M
Float shares
39.36M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2006-04-12
52-week range 5% of range
3.97 9.14

53.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-243.24K net over the window

Short interest

Shares short
2.24M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Gyre Therapeutics (GYRE)?

Gyre Therapeutics last traded at 4.21. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Gyre Therapeutics's market cap?

About 460.79M.

What is the P/E ratio of Gyre Therapeutics?

The trailing twelve-month P/E is -16.19, below its own 5-year average of 62.49 — toward the bottom of its historical range (10.30% percentile). See the Valuation tab for the full history.

Does Gyre Therapeutics pay a dividend?

Gyre Therapeutics does not currently pay a regular dividend.

Is Gyre Therapeutics a buy according to analysts?

The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 18.00, which implies 327.6% upside from the current price. This is not investment advice.

What is Gyre Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Gyre Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Gyre Therapeutics discussion 0 comments

Add a comment